Sen. Ron Wyden and Rep. Frank Pallone, both Democrats, are asking the company for more information about whether EpiPen was classified as a “non-innovator” drug or a brand-name drug by the Medicaid program.
Reuters:
U.S. Lawmakers Question Mylan’s Medicaid EpiPen Rebates
Two key U.S. congressional committee members on Friday called for an investigation into whether Mylan NV, under fire for raising the price of its EpiPen device, overcharged the government’s low-income healthcare program for the allergy treatment. In a letter to the secretary of the Department of Health and Human Services, Senator Ron Wyden and Representative Frank Pallone, both Democrats, seek clarification of whether EpiPen was classified as a generic, “non-innovator” drug, or a brand-name drug by the Medicaid program. (Beasley, 9/2)
The Hill:
Dems Call For Probe Into EpiPen Maker’s Medicaid Charges
Two Democratic congressmen are raising questions about whether Mylan NV, the company facing backlash for raising …
Go to Source